Committed to a
world WITHOUT
Alzheimer’s disease.
Alzheimer’s Therapeutic Research Institute
We are on a path to success in solving the problem of Alzheimer’s Disease (AD). We have a roadmap for our research; build upon amyloid removing treatments, add tau treatments and ultimately prevent the disease altogether.
About UsSave the Date
Anniversary Celebration:
Ten Years Closer to Prevention
Ten Years Closer to Prevention
Saturday, June 14, 2025
Evans Garage Museum, San Diego, CA
Evans Garage Museum, San Diego, CA
Our Impact
We lead the way in AD research
We create rigorous trial designs and analytical approaches.
We have a commitment to open science; sharing data to accelerate discoveries.
We create rigorous trial designs and analytical approaches.
Take Action
How YOU Can Make an
Impact
Here at ATRI we rely on our community to make a difference when it comes to advancing AD research. You can help be a part of that, whether through direct participation or supporting the Institute.
We lead scientific advancements &
understanding of Alzheimer’s disease.
Dr. Alois Alzheimer describes disease
Alzheimer’s Disease Cooperative Study (ADCS) launched. Funded by NIA and
led by Leon Thal
led by Leon Thal
Anti-Amyloid Treatment in Asymptomatic Alzheimer's study
ATRI founded as a San Diego Institute of USC
Alzheimer’s Clinical Trials Consortium (ACTC) formed. Funded by NIA and
led by Aisen, Petersen and Sperling.
led by Aisen, Petersen and Sperling.
Aducanumab receives accelerated approval for treatment of Alzheimer’s
disease
disease
Featured researcher
Cecily Jenkins, PhD
Recently Published Works
Safety, Efficacy, and Feasibility of Intranasal insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial JAMA Neurol. 2020 Sep 1;77(9):1099-1109
Recognitions
Community memory screening as a strategy for recruiting older adults into Alzheimer’s disease research Alzheimers Res Ther. 2020 Jun 30;12(1):78. doi: 10.1186/s13195-020-00643-0
Panels & Presentations
Identification of Alzheimer disease risk by functional magnetic resonance imaging Arch Neurol. 2005 Dec;62(12):1881-8. doi: 10.1001/archneur.62.12.1881.
Press and Media Mentions
January 15, 2025
Ut corrupti quas ea quia exercitationem est neque veritatis et quam aperiam.3
January 15, 2025
Ut corrupti quas ea quia exercitationem est neque veritatis et quam aperiam.
January 15, 2025
Ut corrupti quas ea quia exercitationem est neque veritatis et quam aperiam.1
January 15, 2025
Ut corrupti quas ea quia exercitationem est neque veritatis et quam aperiam.2
Founding director of USC ATRI
Read the Publications
Paul Aisen, MD
Contribution of Alzheimer’s biomarkers and risk factors to cognitive impairment and decline across the Alzheimer’s disease continuum
Using the Alzheimer’s Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer’s disease
The case for low-level BACE1 inhibition for the prevention of Alzheimer’s disease
Learn MoreHow can YOU Take Action
You can help prevent Alzheimer’s. There are a number of ways to take action.
